AmpliPhi Biosciences announces grant of cGMP Certification for its Bacteriophage Facility

AmpliPhi Biosciences on 3rd May, 2015 has announced that it has received good manufacturing practices certification for its bacteriophage facility in Slovenia. AmpliPhi said its facility in Ljubljana, Slovenia has become the first manufacturing site to receive GMP certification to manufacture bacteriophages for human use. AmpliPhi Biosciences cGMP Certification was cleared by JAZMP, the Agency of the Republic of Slovenia for Medicinal Products and Medical Devices, to manufacture bacteriophages under current Good Manufacturing Practices (cGMP) standards. In the press release the company said it will produce Staphylococcus aureus and Pseudomonas aeruginosa bacteriophages to be used in planned human clinical trials. Bacteriophage are naturally occurring viruses that are highly specific for the bacterial hosts they infect.

AmpliPhi BioSciences Corporation (OTCQB: APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. The Company's product development programs target infections that are often resistant to existing antibiotic treatments.